Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Inhibition of atypical protein kinase C‑ι effectively reduces the malignancy of prostate cancer cells by downregulating the NF-κB signaling cascade.

Apostolatos AH, Ratnayake WS, Win-Piazza H, Apostolatos CA, Smalley T, Kang L, Salup R, Hill R, Acevedo-Duncan M.

Int J Oncol. 2018 Nov;53(5):1836-1846. doi: 10.3892/ijo.2018.4542. Epub 2018 Aug 28.

2.

Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay.

Lynch JA, Rothney MP, Salup RR, Ercole CE, Mathur SC, Duchene DA, Basler JW, Hernandez J, Liss MA, Porter MP, Wright JL, Risk MC, Garzotto M, Efimova O, Barrett L, Berse B, Kemeter MJ, Febbo PG, Dash A.

Am J Manag Care. 2018 Jan;24(1 Suppl):S4-S10.

3.

Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer.

Kumar NB, Patel R, Pow-Sang J, Spiess PE, Salup R, Williams CR, Schell MJ.

Oncotarget. 2017 Jun 29;8(58):99093-99103. doi: 10.18632/oncotarget.18858. eCollection 2017 Nov 17.

4.

Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins.

Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, Parnes H, Schell MJ.

Oncotarget. 2016 Oct 25;7(43):70794-70802. doi: 10.18632/oncotarget.12222.

5.

Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention.

Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty J, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn G, Smith T, Yue B, Diaz K, Chornokur G, Crocker T, Schell MJ.

Cancer Prev Res (Phila). 2015 Oct;8(10):879-87. doi: 10.1158/1940-6207.CAPR-14-0324. Epub 2015 Apr 14.

6.

Editorial comment.

Salup RR.

Urology. 2013 Apr;81(4):812; discussion 812. doi: 10.1016/j.urology.2012.10.057. Epub 2013 Feb 13. No abstract available.

PMID:
23414687
7.

Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures.

Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Connors S, Chornukur G, Dickinson SI, Bai W, Williams CR, Salup R, Fu W.

J Cancer Sci Ther. 2012;2011(S3). pii: 007. Epub 2012 Jan 10.

8.

Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures.

Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Anderson K.

J Clin Trials. 2012 Jan 21;2(1). pii: 1000105.

9.

Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer.

Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Slaton J, Anderson JK.

Contemp Clin Trials. 2012 Mar;33(2):279-85. doi: 10.1016/j.cct.2011.11.004. Epub 2011 Nov 11.

10.

Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: a controlled comparison.

Jim HS, Small BJ, Patterson S, Salup R, Jacobsen PB.

Support Care Cancer. 2010 Jan;18(1):21-7. doi: 10.1007/s00520-009-0625-3. Epub 2009 Apr 3.

11.

Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.

Ulloa EW, Salup R, Patterson SG, Jacobsen PB.

Psychooncology. 2009 Jun;18(6):598-605. doi: 10.1002/pon.1427.

PMID:
18942660
12.

Visualization of the neurovascular bundles and major pelvic ganglion with fluorescent tracers after penile injection in the rat.

Davila HH, Mamcarz M, Nadelhaft I, Salup R, Lockhart J, Carrion RE.

BJU Int. 2008 Apr;101(8):1048-51. Epub 2007 Dec 7.

13.

Safety of purified isoflavones in men with clinically localized prostate cancer.

Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J.

Nutr Cancer. 2007;59(2):169-75.

14.

A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer.

Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J.

Nutr Cancer. 2007;59(2):163-8.

15.

Total or partial prostate sparing cystectomy for invasive bladder cancer: long-term implications on erectile function.

Davila HH, Weber T, Burday D, Thurman S, Carrion R, Salup R, Lockhart JL.

BJU Int. 2007 Nov;100(5):1026-9. Epub 2007 Sep 14.

16.

The specific role of isoflavones in reducing prostate cancer risk.

Kumar NB, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R, Pow-Sang J.

Prostate. 2004 May 1;59(2):141-7.

PMID:
15042614
17.

Full-length dominant-negative survivin for cancer immunotherapy.

Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI.

Clin Cancer Res. 2003 Dec 15;9(17):6523-33.

18.

Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer.

Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, Salup R, Jove R, Gabrilovich D.

J Immunol. 2004 Jan 1;172(1):464-74.

19.

Caveolin expression in adult renal tumors.

Carrion R, Morgan BE, Tannenbaum M, Salup R, Morgan MB.

Urol Oncol. 2003 May-Jun;21(3):191-6.

PMID:
12810205
20.

Immunohistochemical expression of Mdm2 and p53 in penile verrucous carcinoma.

Ouban A, Dellis J, Salup R, Morgan M.

Ann Clin Lab Sci. 2003 Winter;33(1):101-6.

PMID:
12661905
21.
22.

Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats.

Bhattachary R, Bukkapatnam R, Prawoko I, Soto J, Morgan M, Salup RR.

Int Immunopharmacol. 2002 May;2(6):783-96.

PMID:
12095169
23.

Expression of the caveolins in dermal vascular tumors.

Morgan MB, Stevens GL, Tannenbaum M, Salup R.

J Cutan Pathol. 2001 Jan;28(1):24-8.

PMID:
11168748
24.

Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins.

Pirtskhalaishvili G, Shurin GV, Esche C, Cai Q, Salup RR, Bykovskaia SN, Lotze MT, Shurin MR.

Br J Cancer. 2000 Aug;83(4):506-13.

25.
26.

Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.

Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R.

Cancer J Sci Am. 1997 Jan-Feb;3(1):21-30.

PMID:
9072304
27.

Leiomyosarcoma with osteoclast-like giant cells of the spermatic cord. A case report and review of the literature.

Konety BR, Singh J, Lyne JC, Salup RR.

Urol Int. 1996;56(4):259-62. Review.

PMID:
8776828
28.

Closure of large postradiation vesicovaginal fistula with rectus abdominis myofascial flap.

Salup RR, Julian TB, Liang MD, Narayanan K, Finegold R.

Urology. 1994 Jul;44(1):130-1.

PMID:
8042254
29.

Chemoimmunotherapy of metastatic murine renal cell carcinoma using flavone acetic acid and interleukin 2.

Salup RR, Sicker DC, Wolmark N, Herberman RB, Hakala TR.

J Urol. 1992 Apr;147(4):1120-3.

PMID:
1552607
30.

Improved lymphocyte cytotoxicity against murine renal cell carcinoma.

Salup RR, Sicker DC, Ballou BT, Flack CE, Wolmark N, Hakala TR.

J Urol. 1992 Feb;147(2):491-5.

PMID:
1732630
31.

Cavernous hemangioma of the adrenal gland.

Salup R, Finegold R, Borochovitz D, Boehnke M, Posner M.

J Urol. 1992 Jan;147(1):110-2.

PMID:
1729495
32.

Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer.

Wiltrout RH, Boyd MR, Back TC, Salup RR, Arthur JA, Hornung RL.

J Immunol. 1988 May 1;140(9):3261-5.

PMID:
3258894
33.

Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.

Vujanovic NL, Herberman RB, Olszowy MW, Cramer DV, Salup RR, Reynolds CW, Hiserodt JC.

Cancer Res. 1988 Feb 15;48(4):884-90.

34.

Adoptive immunotherapy in combination with chemotherapy for cancer treatment.

Wiltrout RH, Salup RR.

Prog Exp Tumor Res. 1988;32:128-53. Review. No abstract available.

PMID:
3287448
35.

Precursor phenotype of lymphokine-activated killer cells in the mouse.

Salup RR, Mathieson BJ, Wiltrout RH.

J Immunol. 1987 Jun 1;138(11):3635-9.

PMID:
3108370
36.

Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy.

Salup RR, Back TC, Wiltrout RH.

J Immunol. 1987 Jan 15;138(2):641-7.

PMID:
3491854
37.

Therapeutic requirements for the successful treatment of murine renal carcinoma by adoptive chemoimmunotherapy.

Wiltrout RH, Mathieson BJ, Back TC, Salup RR.

Prog Clin Biol Res. 1987;244:17-25. No abstract available.

PMID:
3498946
38.

Adoptive immunotherapy of murine mammary carcinoma using broadly cytotoxic cloned T lymphocytes.

Salup RR, Toth JA, Hiserodt JC, Wolmark N.

Prog Clin Biol Res. 1987;244:39-48. No abstract available.

PMID:
2958875
39.

Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes.

Salup RR, Wiltrout RH.

Cancer Res. 1986 Jul;46(7):3358-63. Erratum in: Cancer Res 1986 Oct;46(10):5453.

41.

Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin 2.

Zhang SR, Salup RR, Urias PE, Twilley TA, Talmadge JE, Herberman RB, Wiltrout RH.

Cancer Immunol Immunother. 1986;21(1):19-25.

PMID:
3484675
42.

Role of natural killer activity in development of spontaneous metastases in murine renal cancer.

Salup RR, Herberman RB, Wiltrout RH.

J Urol. 1985 Dec;134(6):1236-41.

PMID:
4057425
43.

Immunomodulation of natural killer activity by polyribonucleotides.

Wiltrout RH, Salup RR, Twilley TA, Talmadge JE.

J Biol Response Mod. 1985 Oct;4(5):512-7.

PMID:
4078596
44.

Therapy of peritoneal murine cancer with biological response modifiers.

Salup RR, Herberman RB, Chirigos MA, Back T, Wiltrout RH.

J Immunopharmacol. 1985;7(4):417-36.

PMID:
3878855
45.

[The usefulness of renal biopsy in the differentiation of various chronic kidney diseases in the child].

Turcanu L, Georgescu L, Salup R, Tudose N.

Monatsschr Kinderheilkd. 1967 Oct;115(10):502-9. German. No abstract available.

PMID:
5591275
46.

[Renal biopuncture and its indications in the nephropathies of childhood].

Salup R, Tudose N, Vasiliu L.

Pediatria (Bucur). 1966 May-Jun;15(3):225-38. Romanian. No abstract available.

PMID:
5960986

Supplemental Content

Support Center